The immune response of B lymphocytes is regulated by antigen, a number of cytokines and perhaps by physical interactions with T cells and accessory cells. In some cases, regulatory species appear to direct different biologic responses by the same B cell. To accomplish this, the B cell presumably must utilize different biochemical mechanisms to convey, or transduce, information generated on the outside of the cell to the inside. Our long term interests lie in the molecular basis of this differential signaling. An ideal model system for analysis of this question exploits the recently described ability of virtually all normal, small B cells to respond to both mIg crosslinking ligands and B cell stimulatory factor 1 (BSF1). It has recently become clear that in small B cells, mIg crosslinking mediated signals are transduced via polyphosphoinositide hydrolysis, Ca++ mobilization and protein kinase C activation. Our preliminary evidence suggests that BSF1 mediated signals may be transduced by a different mechanism. We propose to examine this possibility further and to define the biochemical basis of signal transduction following BSF1 binding by small B cells. Specifically, we propose to: 1. determine whether BSF1 signal transduction occurs via a polyphosphoinositide hydrolysis cascade, 2. determine whether BSF1 modulates the transduction cascade induced by mIg crosslinking ligands, 3. analyze the role of specific """"""""second messenger"""""""" regulated protein kinases in BSF1 mediated signal transduction, and 4. utilize pharmacologic agents to define the cause and effect relationship between early biochemical events defined in Specific Aims 1-3 and later biologic responses to BSF1. For our studies we will use a combination of flow-cytometric and radio biochemical assays. Results of these studies should contribute significantly to our understanding of the molecular basis of regulation of lymphocyte growth and differentiation.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI020519-05
Application #
3130238
Study Section
Allergy and Immunology Study Section (ALY)
Project Start
1983-05-01
Project End
1991-04-30
Budget Start
1987-05-01
Budget End
1988-04-30
Support Year
5
Fiscal Year
1987
Total Cost
Indirect Cost
Name
National Jewish Health
Department
Type
DUNS #
City
Denver
State
CO
Country
United States
Zip Code
80206
Hinman, Rochelle M; Smith, Mia J; Cambier, John C (2014) B cells and type 1 diabetes ...in mice and men. Immunol Lett 160:128-32
Yarkoni, Yuval; Getahun, Andrew; Cambier, John C (2010) Molecular underpinning of B-cell anergy. Immunol Rev 237:249-63
Waterman, Paul M; Cambier, John C (2010) The conundrum of inhibitory signaling by ITAM-containing immunoreceptors: potential molecular mechanisms. FEBS Lett 584:4878-82
Getahun, Andrew; O'Neill, Shannon K; Cambier, John C (2009) Establishing anergy as a bona fide in vivo mechanism of B cell tolerance. J Immunol 183:5439-41
O'Neill, Shannon K; Liu, Edwin; Cambier, John C (2009) Change you can B(cell)eive in: recent progress confirms a critical role for B cells in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 16:293-8
Jin, Lei; Waterman, Paul M; Jonscher, Karen R et al. (2008) MPYS, a novel membrane tetraspanner, is associated with major histocompatibility complex class II and mediates transduction of apoptotic signals. Mol Cell Biol 28:5014-26
Jin, Lei; Stolpa, John C; Young, Ryan M et al. (2008) MHC class II structural requirements for the association with Igalpha/beta, and signaling of calcium mobilization and cell death. Immunol Lett 116:184-94
Gauld, Stephen B; Benschop, Robert J; Merrell, Kevin T et al. (2005) Maintenance of B cell anergy requires constant antigen receptor occupancy and signaling. Nat Immunol 6:1160-7
Jordan, Michael B; Mills, David M; Kappler, John et al. (2004) Promotion of B cell immune responses via an alum-induced myeloid cell population. Science 304:1808-10
Mills, David M; Stolpa, John C; Cambier, John C (2004) Cognate B cell signaling via MHC class II: differential regulation of B cell antigen receptor and MHC class II/Ig-alpha beta signaling by CD22. J Immunol 172:195-201

Showing the most recent 10 out of 49 publications